



Universiteit  
Leiden  
The Netherlands

## Genome-wide methylation patterns in Marfan syndrome

Andel, M.M. van; Groenink, M.; Berg, M.P. van den; Timmermans, J.; Scholte, A.J.H.A.; Mulder, B.J.M.; ... ; Waard, V. de

### Citation

Andel, M. M. van, Groenink, M., Berg, M. P. van den, Timmermans, J., Scholte, A. J. H. A., Mulder, B. J. M., ... Waard, V. de. (2021). Genome-wide methylation patterns in Marfan syndrome. *Clinical Epigenetics*, 13(1). doi:10.1186/s13148-021-01204-4

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3279776>


**Note:** To cite this publication please use the final published version (if applicable).

RESEARCH

Open Access



# Genome-wide methylation patterns in Marfan syndrome

Mitzi M. van Andel<sup>1\*</sup> , Maarten Groenink<sup>1,2</sup>, Maarten P. van den Berg<sup>3</sup>, Janneke Timmermans<sup>4</sup>, Arthur J. H. A. Scholte<sup>5</sup>, Barbara J. M. Mulder<sup>1</sup>, Aeilko H. Zwinderman<sup>6†</sup> and Vivian de Waard<sup>7†</sup>

## Abstract

**Background:** Marfan syndrome (MFS) is a connective tissue disorder caused by mutations in the Fibrillin-1 gene (FBN1). Here, we undertook the first epigenome-wide association study (EWAS) in patients with MFS aiming at identifying DNA methylation loci associated with MFS phenotypes that may shed light on the disease process.

**Methods:** The Illumina 450 k DNA-methylation array was used on stored peripheral whole-blood samples of 190 patients with MFS originally included in the COMPARE trial. An unbiased genome-wide approach was used, and methylation of CpG-sites across the entire genome was evaluated. Additionally, we investigated CpG-sites across the FBN1-locus (15q21.1) more closely, since this is the gene defective in MFS. Differentially Methylated Positions (DMPs) and Differentially Methylated Regions (DMRs) were identified through regression analysis. Associations between methylation levels and aortic diameters and presence or absence of 21 clinical features of MFS at baseline were analyzed. Moreover, associations between aortic diameter change, and the occurrence of clinical events (death any cause, type-A or -B dissection/rupture, or aortic surgery) and methylation levels were analyzed.

**Results:** We identified 28 DMPs that are significantly associated with aortic diameters in patients with MFS. Seven of these DMPs (25%) could be allocated to a gene that was previously associated with cardiovascular diseases (HDAC4, IGF2BP3, CASZ1, SDK1, PCDHGA1, DIO3, PTPRN2). Moreover, we identified seven DMPs that were significantly associated with aortic diameter *change* and five DMPs that associated with clinical events. No significant associations at  $p < 10^{-8}$  or  $p < 10^{-6}$  were found with any of the non-cardiovascular phenotypic MFS features. Investigating DMRs, clusters were seen mostly on X- and Y, and chromosome 18–22. The remaining DMRs indicated involvement of a large family of protocadherins on chromosome 5, which were not reported in MFS before.

**Conclusion:** This EWAS in patients with MFS has identified a number of methylation loci significantly associated with aortic diameters, aortic dilatation rate and aortic events. Our findings add to the slowly growing literature on the regulation of gene expression in MFS patients.

**Keywords:** Marfan syndrome, EWAS, Methylation loci, Aortic diameters, Clinical events

## Introduction

Marfan syndrome (MFS) is a dominant autosomal disorder caused by mutations in the Fibrillin-1 (FBN1) gene, which results in a connective tissue defect. FBN1 is a relatively large gene consisting of 65 exons that encodes the proprotein profibrillin-1, consisting of 2871 amino-acids, which is proteolytically cleaved into fibrillin-1 and the hormone asprosin. Over 3000 pathogenic variations have been reported [1]. MFS has diverse phenotypic

\*Correspondence: m.m.vanandel@amsterdamumc.nl

†Aeilko H. Zwinderman and Vivian de Waard have contributed equally to this work

<sup>1</sup> Department of Cardiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Full list of author information is available at the end of the article



expression covering skin, lungs, eyes, joints, bones, the spinal cord and in the cardiovascular system. Mitral valve prolapse and aortic aneurysms in the heart and the aorta, respectively, determine the increased risk for cardiovascular morbidity and mortality.

There is large phenotypic variation, also within families with members carrying the same genetic mutation. Different patient-characteristics have been evaluated as explanatory factors for the phenotypic diversity. The multitude in FBN1-mutations, leading to for example defining dominant negative or haploinsufficient FBN1-expression phenotypes, have been implicated in disease severity and response to pharmaceutical treatments [2–6]. An altered distribution of FBN1 transcript isoforms has been identified between MFS patients and unaffected individuals [7]. Moreover, the abundance of the wild-type allele expression of the FBN1 gene may contribute to disease severity [8]. Also, genetic variations in other genes at other chromosomal loci have been reported to be associated with enhanced aorta pathology MFS, such as COL4A1 and PRKG1, which are considered genetic modifiers [9]. It is anticipated that variants in more aneurysm-related genes will be discovered to affect MFS phenotype.

Association of increased blood levels of elastin fragments (desmosine), transforming growth factor beta (TGF- $\beta$ ), microfibrillar associated protein 4 (MFAP4), or homocysteine with enhanced aorta pathology is described in MFS [10–13].

Recently, DNA-hypomethylation patterns of CpG-island shores of the FBN1-gene were associated with the level of FBN1 gene expression in porcine liver and fetal fibroblasts, showing its involvement in tissue/cell-type-specific gene expression [14]. To our knowledge, no other studies concerning the role of methylation patterns in MFS patients have been performed yet. Differential methylation patterns of the FBN1 locus have been observed; however in other patient populations, hypermethylation of the FBN1 gene is identified as biomarker for multiple cancers [15–17]. Although it is unclear how these results generalize to MFS-patients, it illustrates that differential methylation patterns impact FBN1-expression and may thus be associated with MFS phenotypic diversity.

With the current study we described the association between a snapshot of the genome-wide DNA-methylation levels and different MFS phenotypes in a subgroup of the patients who were included in the COMPARE trial on the effect of losartan [18]. DNA-methylation was measured using the Illumina 450 K chip with DNA derived from stored peripheral whole-blood samples (taken at baseline) of 190 participants. We used an unbiased genome-wide approach and thus evaluated methylation of CpG-sites across the entire genome. Because MFS

is caused by mutations in the FBN1 gene, we also looked in particular at CpG-sites up- and downstream from the FBN1-locus (15q21.1).

## Methods

### Study population

This study is part of the COMPARE study on efficacy of losartan treatment to reduce growth of the aortic root and thoracic aorta diameter in patients with MFS. Details of the design and data collection [19] are described elsewhere as well as of the primary results [18]. In brief, the COMPARE study was a multicenter randomized clinical trial randomizing 233 patients with MFS between losartan 50 and 100 mg daily on top of usual treatment versus usual treatment for 3 years. MFS was established according to the revised Ghent criteria, all patients were > 18 years of age, had diameters < 50 mm at baseline, did not have > 1 surgical repair of aortic aneurysms and were not scheduled for surgery. Diameters of the aortic root and thoracic aorta were measured at seven anatomical locations at baseline and after 3 years, by Magnetic Resonance Imaging (MRI) or by Computed Tomography (CT) imaging. Losartan was found to significantly reduce growth of the diameter of the aortic root. Ethical approval was obtained from the ethics committees of all hospitals from which patients were included. Written informed consent was obtained from all study patients.

The methylation-wide association study was performed using a subset of all 194 patients of whom stored whole-blood was available from baseline.

### Phenotypic measurements

*Primary outcomes* for the present study were the baseline diameters of the aorta, measured at seven anatomical aortic landmarks. Aortic diameters were measured on the MRI and CT scans; the aortic root, the ascending and descending thoracic aorta at the level of the pulmonary bifurcation, the aortic arch, the descending thoracic aorta at the level of the diaphragm and the abdominal aorta just proximal to the aortic bifurcation. See Groenink et al. [18] for a detailed description of MRI, and CT acquisitions. Aortic root diameter was assessed by greatest end-diastolic diameter of three cusp-cusp dimensions from the outer to inner wall on the steady-state free-precession images. All measurements beyond the aortic root were performed on multiplanar magnetic resonance angiography reconstructions from inner to inner edge.

*Secondary outcomes* were presence or absence at baseline of 21 clinical features of MFS: ectopia lentis, myopia, flat cornea, increased axial eye-length, hypoplastic iris, thumb/wrist sign, pectus carinatum, pectus excavatum, hindfoot deformity, pes planus, pneumothorax, dural ectasia, protrusio, increased height-span ratio, scoliosis,

reduced elbow extension, facial features, striae, joint problems, arched palate, and mitral valve prolapse. We also evaluated the Marfan disease systemic score [20], which is a weighted sum of the mentioned MFS clinical features. Presence or absence of the MFS features was taken from electronic patient files.

Moreover, we evaluated the association of the changes in aortic diameter with methylation levels during the 3-year trial. Change was calculated as the absolute difference between diameters measured after the 3 years follow-up of the trial minus the diameters measured at baseline.

Lastly, we analyzed the association between methylation levels and the occurrence of clinical events (death any cause, type-A or -B dissection/rupture, or aortic surgery) over a median follow-up of 8 years [21].

Missing values were multiply imputed and all results that we report below were based on observed and imputed values. We performed a sensitivity analysis based on observed values only, and these results were similar to what was found with observed and imputed data (Additional file 1: Figure SA1). Distributions of the baseline diameters and their changes were normally distributed within a reasonable range in our patient samples, but a few large diameters were observed at the diaphragm and bifurcation, and were characterized as outliers (Additional file 1: Figures SB1 and SB2). Baseline diameters were substantially correlated with each other (varying from 0.21 to 0.79), and their first principal component explained about 57% the total variance in the diameters at the seven landmarks. We also evaluated therefore the association between methylation levels and the mean diameter calculated over the seven landmarks, but this did not add any new insights.

#### DNA methylation profiling and processing

DNA extraction and methylation profiling were performed on whole-blood, available from baseline (2008–2009). Bisulfite DNA treatment was achieved using the Zymo EZ DNA Methylation™ kit, and the quality of the conversion was determined by high-resolution melting analyses. The converted DNA was amplified and hybridized on the Illumina Human Methylation 450 K array, which measured DNA methylation levels of approximately 485,000 CpG sites. The samples were randomly divided over three bisulfite conversion and hybridization batches.

Raw 450 K data were processed for primary quality control using the statistical language R (version 4.0.3) and various packages (methylAid, minfi). Bad quality samples were detected using sample dependent and the sample-independent control CpG sites present on the 450 K array itself. Threshold values for defining bad quality samples

were: methylated and unmethylated intensities of 10.5, overall quality control = 11.75, bisulfite control = 12.75, hybridization control of 12.50, and detection  $p$  value of 0.95. Based on these thresholds, four samples were considered outliers (Additional file 1: Figure SC1). This resulted in a sample size of 190 for the current analyses.

Functional normalization was applied using the pre-process Funnorm function of the R-minfi package to normalize raw 450 K data. Principal component analysis (PCA) on the normalized dataset annotated for sex, age, body surface area, recruitment site, bisulfite batch, hybridization batch and plate position revealed no other quality concerns (Additional file 1: Figure SC2). Principal components 1 and 2 explained 30% of the variance.

We discarded CpG sites referring to single nucleotide polymorphisms and single base extensions, and this resulted in a set of 467,971 CpG sites which was used to identify differentially methylated positions (DMP) and differentially methylated regions (DMRs) in the regression analyses. There were 4414 methylation measurements with detection  $p$  values larger than 0.05 (0.0048%), and for 463,557 CpG sites all detection  $p$  values were smaller than 0.05. Per patient, the number of CpG sites with methylation detection  $p$  values  $> 0.05$  varied between 9 and 1117 with median 271 (Q1–Q3: 61–259).

Cell composition of the whole-blood samples was estimated using the method proposed by Houseman et al. [22]. Cell-type distribution variables were used as covariates in the regression analyses: percentage of CD8<sup>+</sup> T-cells, CD4<sup>+</sup> T-cells, B-cells, NK-cells, Monocytes, Neutrophils and Eosinophils.

#### Statistical analysis

##### *Differentially methylated positions (DMPs)*

Linear, logistic and Cox regression analyses were performed in R. Aorta diameters, their change, MFS features and the occurrence of events were the dependent variables. DNA methylation M-levels were the independent variables of main interest. Age, sex, body surface area (BSA), estimated cell counts were included as covariates. The methylation principal components had high multivariate correlation with the cell-type distribution variables (first canonical correlation 0.9927) and were therefore not included as covariates. Because of the low incidence, we only performed univariate Cox regression analysis on the combined clinical events.

For all DMP analyses, M-values were calculated as the log<sub>2</sub> ratio of the intensities of methylated probes versus unmethylated probes. The results of the regression analyses were presented as regression weights with corresponding standard errors and  $p$  values. We also analyzed the methylation Beta-values. Because Beta-values are logit-transformations of the M-values (times log(2)),

results of the analyses with Beta-values were highly similar to those using M-values, and we focus therefore only on M-values.

#### Differentially methylated regions (DMRs)

To identify DMRs we smoothed per chromosome the estimated regression coefficients of the regression models of phenotypes on the 467,971 M-values inversely weighted by the associated squared standard errors. We used a loess-smoother with span-width 0.01 for M-values on all autosomes and 0.1 for M-values on the Y-chromosome.

We defined a DMR as three or more CpG sites in a cluster. Statistical significance of DMRs was obtained from bootstrapping, but because the choice of the span-width of the loess-smoother was based on subjective visual inspection only, significance levels should be interpreted with caution.

Gene-enrichment analysis of genes associated with identified DMPs or DMRs was performed with Panther (version 16.0) through geneontology.org and genemania.org.

## Results

### Description of the MFS patient population

Patient characteristics and disease phenotypes are summarized in Tables 1 and 2. Average age was 38 years (SD 13) and there were 103 male and 87 female patients.

Average baseline aortic diameters at the seven anatomical landmarks were 45, 29, 24, 24, 21, 21, and 16 mm, from aortic root to aortic bifurcation, respectively. Average increases of the diameters during the 3-year trial were 1.23, 0.84, 0.57, 0.53, 0.81, 0.33, and 0.46 mm, respectively. There were few missing baseline diameters at the bifurcation, because the MRI/CT images did not

extend to that landmark. Baseline diameters of the root and ascending aorta were missing in 52 patients because of previous aortic surgery. A number of values for the change in diameter were missing because of aortic surgery during the 3-year follow-up of the trial. Prevalence of non-cardiovascular Marfan features varied between 3% (Protrusio) and 67% (Striae).

As expected, diameters showed significant positive correlation with age and BSA, and male patients had significantly larger diameters than female patients. Diameters also showed significant correlations with cell-type fractions, especially negatively with percentage of CD8<sup>+</sup> T-cells (corr > -0.22,  $p < 0.0022$ ). There were 51 patients with clinical events during the 8 years follow-up. There were two aortic ruptures, 13 aortic dissections and 38 patients underwent aortic surgery. Five patients died (three after dissection/rupture, one had aortic surgery first). The Kaplan–Meier curve is given in Additional file 1: Figure SD1.

### Differentially methylated positions associated with aortic diameters

We identified differentially methylated positions that are associated with aortic diameters. The  $p$  values of the regression analyses of all baseline aorta diameters and MFS features on all M-values corrected for sex, age, BSA, and cell-types are summarized in Fig. 1. In total there were eight CpG-sites with genome-wide significant association ( $p < 10^{-8}$ ) with baseline aortic diameters, at the diaphragm and bifurcation level (Table 3, bold). Of these eight CpG sites, six are close to, or in known genes.

At a level of significance of  $p < 10^{-6}$ , there were 28 sites significant; one each with diameters at the aortic root, in the ascending aorta and aortic arch, two in the proximal descending aorta, and 14 and 9 at the diaphragm and bifurcation level, respectively (Table 3). Manhattan-plots as well as scatterplots illustrating the significant associations are given in Additional file 1: Figures SD2 and SD3.

Of these 28 CpG sites with a significance of  $p < 10^{-6}$ , 19 CpG sites could be allocated to a gene (including the six with  $p$  value  $p < 10^{-8}$ ) (Table 3). Upon studying these genes for a possible role in MFS, four genes (FNBP1, EHBP1, SDK1, and PTPRN2) were found to be involved in cytoskeletal actin dynamics, which regulates cell-adhesion and cellular uptake or secretion [23–26], which is altered in MFS cells [27], and thought to play a role in aneurysm formation [28].

Most interestingly in relation to aortic diameters, seven genes were found to have a known role in the cardiovascular system, of which HDAC4 is the most widely studied in cardiovascular disease.

HDAC4 is a histone deacetylase with very weak histone deacetylase activity. It actually can modulate histone

**Table 1** Baseline characteristics

	Total $n = 190$
<i>Patient characteristics</i>	
Sex, male	103 (54%)
Age, years	38 ± 13
Body surface area (m <sup>2</sup> )	2.02 ± 0.24
<i>Estimated cell fractions (%)</i>	
B cells	4 ± 3
NK cells	5 ± 4
CD4 <sup>+</sup> T cells	17 ± 6
CD8 <sup>+</sup> T cells	4 ± 3
Neutrophils	59 ± 10
Monocytes	10 ± 3
Eosinophils	0.1 ± 0.8

Plus-minus values are means ± SD

**Table 2** (A) Aortic diameter and aortic dilatation rate by MRI. (B) Non-cardiovascular Marfan features

	Aortic diameters <sup>a</sup>		Aortic diameter change <sup>b</sup>
A			
<i>Aortic dimension by MRI</i>			
Aortic root (mm)		45 ± 5.6	1.23 ± 2.10
Ascending aorta (mm)		29 ± 3.9	0.84 ± 1.39
Aortic arch (mm)		24 ± 3.1	0.57 ± 1.47
Proximal descending aorta (mm)		24 ± 3.5	0.53 ± 1.54
Distal descending aorta (mm)		21 ± 3.1	0.81 ± 1.57
Diaphragm (mm)		21 ± 3.2	0.33 ± 1.21
Bifurcation		16 ± 3.6	0.46 ± 1.83
<b>Marfan features</b>		<b>Marfan features</b>	
B			
Ectopia Lentis	88 (46%)	Dural ectasia	98 (52%)
Myopia	37 (19%)	Protrusio	5 (3%)
Flat cornea	15 (8%)	Increased height-span ratio	37 (19%)
Increased axial eye-length	25 (13%)	Scoliosis	50 (26%)
Hypoplastic iris	17 (9%)	Reduced elbow extension	25 (13%)
Thumb/wrist signs	83 (44%)	Facial features	56 (29%)
Pectus carinatum	66 (35%)	Striae	128 (67%)
Pectus excavatum	29 (15%)	Joint problems	48 (25%)
Hindfoot deformity	56 (29%)	Arched palate	119 (63%)
Pes planus	83 (44%)	Mitral valve prolapse	104 (55%)
Pneumothorax	28 (15%)		

Summary statistics are based on observed values and imputations of missing values

<sup>a</sup> Data are diameters at baseline

<sup>b</sup> Data are change in millimeter per 3 years

methylation, which contributes to regulation of gene transcription [29]. Reviews on HDAC4 reveal functions for this protein in development of cardiac hypertrophy and remodeling [30, 31]. Apart from cardiac muscle functions, HDAC4 also plays a role in smooth muscle cell development and phenotype [32–37]. Smooth muscle cell phenotype switching is observed in the aorta of MFS mice and in human ascending aortic aneurysm tissue [38, 39].

**IGF2BP3** and **CASZ1** have key functions in cardiac development, since defects in these genes lead to congenital heart disease [40–43]. **SDK1** and **CASZ1** variants are associated with hypertension [44, 45]. In addition, a SNP in **PCDHGA1** is associated with carotid artery–intima media thickness (IMT) in humans as readout of atherosclerosis [46], and **DIO3** is enhanced in cardiac tissue in heart failure and ventricular remodeling [47, 48].

For a number of these genes DNA methylation differences relate to cardiovascular disease. Hypomethylation of the HDAC4 gene promoter in genomic DNA from peripheral blood of obese adults compared to non-obese


controls shows a strong correlation with reduced brachial artery flow-mediated dilation (FMD) and insulin signaling, as readout of vascular (dys)function [49]. Reduced FMD is also observed in MFS patients and correlates to aortic diameters [50, 51]. DNA methylation in placental tissue at sites encoding **PTPRN2** and **CASZ1** are associated with cardiometabolic disease in adulthood [52], and DNA methylation in blood leukocytes at the location of the **PTPRN2** gene is associated with future myocardial infarction [53].

#### Differentially methylated positions associated with non-cardiovascular phenotypes

No significant associations at  $p < 10^{-8}$  or  $p < 10^{-6}$  were found with any of the non-cardiovascular phenotypes MFS features (Additional file 1: Figure SD4).

#### Differentially methylated positions associated with aortic diameter change or aortic events

Apart from associations with aortic diameters, there were seven CpG sites with methylation levels associated



**Fig. 1** Minus  $10 \log(p \text{ values})$  of the associations of methylation M-values and Beta-values at the 467,971 CpG sites with each of the baseline aortic diameters and Marfan features (so, every column consists of  $2 \times 467,971$   $p$  values). The dotted green and red lines correspond to 8.5 and 6 indicating  $p$  values of  $8.5 \times 10^{-8}$  and  $1 \times 10^{-6}$ , respectively

( $p < 10^{-6}$ ) with aortic diameter *change* and five CpG sites associated with the occurrence of clinical events. Details of these CpG sites are given in Table 4. Manhattan-plots and scatterplots are given as Additional file 1: Figures SD5 and SD6.

Within the seven CpG sites that relate to aortic diameter *change*, four genes located in or in close proximity to these CpG sites have a known cardiovascular function, namely **LSAMP**, **DSCAM**, **SEMA3A**, **PRRX2**. LSAMP has been shown to influence smooth muscle cell proliferation [54], and LSAMP variants are associated with survival in coronary artery disease patients [55]. DSCAM overexpression leads to congenital heart defects [56] and is probably responsible for the congenital heart defects observed in Down syndrome patients [57]. Moreover, SEMA3A and PRRX2 mutations also lead to congenital heart defects [58, 59]. Next to its function in the heart, both proteins also influence smooth muscle development. SEMA3A is mechanosensitive and influences

smooth muscle cell recruitment for vascular maturation [60], while deficiency of PRRX2 leads to malformations of the aorta in mice [61].

Within the five CpG sites that relate to aortic events, three genes located in or in close proximity to these CpG sites have a known cardiovascular function, namely **MEF2D**, **TNS1** and **HHIPL1**. Of these genes MEF2D is most widely studied in cardiovascular disease, since the family of MEF2 transcription factors is regulators of skeletal, cardiac and smooth muscle cell development [62]. TNS1 connects extracellular matrix to the cytoskeletal interior [63]. Alterations in TNS1 lead to cardiac valve defects causing mitral valve prolapse [64, 65], as is also observed in MFS patients [66]. Finally, variants in HHIPL1 are associated with myocardial infarction, increased blood pressure and coronary artery disease, probably in part, because smooth muscle cell-derived HHIPL1 enhances atherosclerosis as reported in two hyperlipidemic mouse models [67, 68]. The methylation

**Table 3** CpG-sites with genome-wide significant association with baseline aortic diameters ( $p < 10^{-6}$ )

Aorta diameter	CpG	CHR	Position	Strand	Gene	UCSC_CpG_Islands_Name	$\beta$ value	SE	p value	Cardiovascular function
Aortic root	cg20074307	14	55,092,491	F	SAMD4A		-7.328698	1.42835322	7.81E-07	
Ascending aorta	cg25190999	2	8,826,175	F		chr2: 8825106-8826188	-7.3255838	1.41517063	6.33E-07	
Aortic arch	cg13399952	9	132,652,889	F	FNBP1	chr9: 132652350-132652715	3.259245	0.59292635	1.39E-07	
Proximal desc aorta	cg22162225	2	62,932,835	R	EHBP1	chr2: 62932595-62933353	-3.9168576	0.75191428	5.44E-07	
Proximal desc aorta	cg04258811	15	84,976,641	F		chr15: 84976070-84977044	2.73851672	0.47139499	3.02E-08	
Aorta at diaphragm	cg11825706	1	201,552,873	R			-2.9891322	0.55625272	2.51E-07	
Aorta at diaphragm	cg10045864	2	240,036,897	F	HDAC4	chr2: 240033147-240033453	-5.1346472	0.89881755	4.87E-08	Cardiac hypertrophy and remodeling Aortic aneurysm formation Vascular dysfunction
Aorta at diaphragm	cg18487516	6	3,849,542	F	FAM50B	chr6: 3849271-3851048	-6.2306009	1.03917257	1.18E-08	
<b>Aorta at diaphragm</b>	<b>cg07829265</b>	<b>7</b>	<b>4,308,166</b>	<b>F</b>	<b>SDK1</b>	<b>chr7: 4303079-4305062</b>	<b>-3.9305036</b>	<b>0.62392327</b>	<b>2.47E-09</b>	<b>Hypertension</b>
Aorta at diaphragm	cg05852760	7	23,508,224	F	IGF2BP3	chr7: 23508184-23509712	-3.0209111	0.52917492	4.97E-08	Congenital heart disease
Aorta at diaphragm	cg21375490	7	157,411,039	F	PTPRN2	chr7: 157409846-157410241	-4.9468079	0.95539399	6.29E-07	Future myocardial infarction
<b>Aorta at diaphragm</b>	<b>cg07701530</b>	<b>10</b>	<b>22,911,629</b>	<b>F</b>	<b>PIP4K2A</b>		<b>-1.862081</b>	<b>0.29196299</b>	<b>1.64E-09</b>	
<b>Aorta at diaphragm</b>	<b>cg26558664</b>	<b>11</b>	<b>18,230,491</b>	<b>F</b>	<b>LOC494141</b>	<b>chr11: 18230619-18230906</b>	<b>-1.1258168</b>	<b>0.18214965</b>	<b>4.58E-09</b>	
Aorta at diaphragm	cg04838249	12	34,500,640	F		chr12: 34500550-34500814	3.92396387	0.65291884	1.10E-08	
Aorta at diaphragm	cg05265042	14	102,030,999	F	DIO3	chr14: 102025989-102031567	2.89385142	0.54443147	3.31E-07	Heart failure Ventricular remodeling
<b>Aorta at diaphragm</b>	<b>cg09689342</b>	<b>16</b>	<b>5,077,985</b>	<b>F</b>	<b>NAGPA</b>		<b>-4.945524</b>	<b>0.75454621</b>	<b>6.42E-10</b>	
<b>Aorta at diaphragm</b>	<b>cg02472906</b>	<b>16</b>	<b>87,938,341</b>	<b>F</b>	<b>CA5A</b>		<b>-5.0764489</b>	<b>0.84196725</b>	<b>9.96E-09</b>	
Aorta at diaphragm	cg06906965	19	58,450,175	R		chr19: 58446336-58446800	-3.9017762	0.73555419	3.48E-07	
Aorta at diaphragm	cg27614967	23	153,561,283	F		chrX: 153561035-153561361	-5.0488276	0.87988599	4.30E-08	
<b>Aorta at bifurcation</b>	<b>cg24073777</b>	<b>1</b>	<b>10,832,698</b>	<b>F</b>	<b>CASZ1</b>		<b>-9.4883778</b>	<b>1.54559989</b>	<b>5.68E-09</b>	<b>Congenital heart disease</b> <b>Hypertension</b>
<b>Aorta at bifurcation</b>	<b>cg03158772</b>	<b>3</b>	<b>14,768,188</b>	<b>F</b>	<b>C3orf20</b>		<b>-6.4625567</b>	<b>1.0591771</b>	<b>6.89E-09</b>	
Aorta at bifurcation	cg24324446	3	110,363,281	F			-4.3209801	0.79936682	2.16E-07	
Aorta at bifurcation	cg05149776	5	140,870,164	R	PCDHGA1	chr5: 140871064-140872335	-5.8834917	1.0294066	4.81E-08	Atherosclerosis
Aorta at bifurcation	cg24588058	7	76,591,673	F		chr7: 76588998-76589608	-4.9102623	0.94591786	5.91E-07	
Aorta at bifurcation	cg19804570	18	44,618,587	R	KATNAL2		-5.4528539	1.01978524	2.85E-07	
Aorta at bifurcation	cg18075379	20	61,788,662	F		chr20: 61788160-61788669	-5.1667712	0.95877471	2.34E-07	
Aorta at bifurcation	cg14798310	22	24,234,197	F	MIF-AS1	chr22: 24236257-24237539	-4.8972641	0.88169036	1.06E-07	
<b>Aorta at bifurcation</b>	<b>cg27504079</b>	<b>23</b>	<b>50,653,533</b>	<b>R</b>	<b>BMP15</b>		<b>-3.9887835</b>	<b>0.65665158</b>	<b>7.91E-09</b>	

In yellow the significant associations with  $p < 10^{-8}$

**Table 4** CpG-sites with genome-wide significant association ( $p < 10^{-6}$ ) with change in aortic diameter or aortic events

Aortic dilatation rate	CpG	CHR	Position	Strand	Gene	UCSC_CpG_Islands_Name	$\beta$ value	SE	p value	Cardiovascular function
Aortic root	cg00702593	21	42,219,853	F	DSCAM	chr21:42218489-42219222	-2.32E+00	4.56E-01	9.58E-07	Congenital heart disease
Proximal des aorta	cg05230977	20	62,039,853	F	KCNQ2	chr20:62037929-62038677	2.24E+00	4.25E-01	4.24E-07	
Distal des aorta	cg17213304	5	78,364,769	R	DMGDH	chr5:78365298-78365711	3.68E+00	7.15E-01	7.15E-07	
Aorta at bifurcation	cg26033586	3	116,163,858	R	LSAMP					Smooth muscle cell development Coronary artery disease
Aorta at bifurcation	cg24219974	6	14,729,722	F						
Aorta at bifurcation	cg16346212	7	83,824,255	R	SEMA3A					Congenital heart disease Smooth muscle cell development
Aorta at bifurcation	cg13713739	9	132,483,377	R	PRRX2	chr9:132481472-132481745				Congenital heart disease Malformation in aorta
<i>Aortic events</i>										
Aortic events	cg05371909	1	156,426,550	R	MEF2D	chr1:156426549-156427362	6.797315	1.2097795	1.92E-08	Smooth muscle cell development
Aortic events	cg04316429	2	218,844,202	R	TNS1	chr2:218843460-218843742	-3.894949	0.7743331	4.90E-07	Cardiac valve defects
Aortic events	cg20852788	4	119,676,722	F	SEC24D		2.192283	0.4360381	4.96E-07	
Aortic events	cg17369115	6	947,6450	F	LOC100506		-3.724896	0.7524573	7.41E-07	
Aortic events	cg02283151	14	100,110,845	F	HHIPL1	chr14:100111120-100111906	-8.5573	1.7356909	8.21E-07	Myocardial infarction Hypertension Coronary artery disease


state of these CpG-sites could influence gene expression levels and may represent functional involvement of the genes they represent in the methylation profile of the white blood cell is similar in the cardiovascular tissue.

Association of time to first clinical event with methylation levels at cg05371909 (MEF2D) and cg17369115 is illustrated in Fig. 2 with Kaplan–Meier curves defined

by the quartiles of the methylation distributions. Here we show examples of a hyper- and hypomethylation associated with CpG site with events.

**Differentially methylated regions**

Smoothed standardized regression weights of baseline phenotypes on M-values and of aortic diameter *change*



**Fig. 2** Kaplan–Meier curves of time to first clinical event in subgroups defined by quartiles of the distribution of methylation levels at 2 CpG sites, representing hypermethylation of cg05371909 site (MEF2D) or hypomethylation of the cg17369115 site (LOC100506) is associated with events


and clinical *events* were done on M-values. We zoomed in on the association of the incidence of clinical events with M-values of CpG-sites in and close to the FBN1-gene in Fig. 3, but no significant DMRs were observed for this region.

In total 95 putative DMRs were found with baseline phenotypes and 34 with diameter *change* and clinical *events* of which 15+9 and 3+10, respectively, were located on the X- and Y-chromosomes. Of the 71 and 21 other DMRs, 45 and 17 DMRs were located on chromosomes 18 to 22. Because these chromosomes are smaller with fewer CpGs, we think that DMRs on these chromosomes are more susceptible for the choice of the span-width of the loess-smoother and are therefore less reliable. Numbers of DMRs on other chromosomes were mostly 0 or 1, with the exception of chromosome 5, where 14 DMRs for baseline phenotypes are found.

CpGs in the 95 and 34 DMRs involved in baseline phenotypes and aortic diameter *change* and clinical *events*

were located in or in close proximity of 63 and 49 genes, respectively, with 25 genes overlapping in both sets of DMRs (Additional file 1: Table sT1). Among the genes behind the DMRs there were two well-known cardiovascular transcription factors, namely Notch1 and Tbx1, which are also involved in cardiovascular development [69, 70]. When combining these two gene lists, gene-set enrichment with gene ontology and genemania showed that genes in the ‘homophilic cell adhesion via plasma membrane adhesion molecules’ as biological process and ‘calcium dependent cell-cell adhesion’ in particular, were enriched (13/18 in the lists versus 0.36/0.42 as expected:  $p$  values =  $4.16e-16$  and  $5.57e-26$ , FDR =  $6.61e-12$  and  $8.84e-22$ , respectively).

It becomes evident that the largest group of genes represents a protocadherin gene cluster on chromosome 5. These genes have an immunoglobulin-like organization; the genomic DNA sequences encoding their ectodomains are not interrupted by an intron, thus these genes



have unusually large exons, next to three constant exons that they all have in common [71]. Protocadherins are involved in cell adhesion and have been shown to regulate tissue development, and many of them are expressed in the heart [72]. Among the protocadherin genes are the previously mentioned PCDHGA1, but also PCDHGA4, of which mutations lead to atrial septal defects [43], PCDHA9 mutations playing a role in valvular defects [73], and altered PCDHGA3 gene expression is strongly associated with reduced stroke volume and ventricular dysfunction [74].

By identification of DMRs, the large number of genes in proximity of these regions allow for gene-set enrichment analysis to unravel pathways that are overrepresented. Here, the protocadherin gene cluster largely determines the identified pathway of altered cell adhesion.

## Discussion

### Key findings

Our EWAS study identifies genetic loci potentially influencing characteristic features of patients with MFS. Among the identified differentially methylated genetic loci in or near candidate genes, several of these genes have been implicated in other cardiovascular phenotypes, potentially also affecting cardiac and/or aortic phenotype in MFS. Twenty-eight DMPs that were identified associated with baseline aortic diameters, seven DMPs with aortic diameter *change*, and five DMPs with clinical *events*. No DMPs were significantly associated with the other 21 MFS features that were analyzed. As for the DMRs, the large number of DMRs and related genes allowed gene-set enrichment analysis, which revealed the process of cell adhesion, that could for a large part be traced back to a cluster of protocadherins on chromosome 5. The relevance of these protocadherins in MFS still has to be determined. No methylation loci were identified in the FBN1 gene vicinity to associate with MFS phenotype.

### Discussion of the key findings

Based on findings from others [8, 14, 17], it was anticipated we would identify differently methylated loci surrounding the FBN1 gene that may influence FBN1 expression. However, we were not able to strengthen these results with our own findings.

Regarding the DMPs, it was striking that a number of the underlying genes had a known cardiovascular function, since these DMPs are identified in DNA of peripheral whole-blood samples, thus DNA of white blood cells. Of these genes, the cardiovascular function often represented cardiovascular development. This suggests activation of tissue repair processes, since wound healing is known to activate the fetal gene program [75]. If the

DMPs in the white blood cells are similarly affected in the cardiovascular tissues remains to be determined. Only then, these genes may be functionally involved to serve as potential target for treatment to halt aortic aneurysm growth

Even though we detected only a small number of statistically significant differentially methylated CpG sites in DNA of whole-blood samples that are associated with aortic characteristics, these DMPs may be followed up for validation to potentially serve as biomarkers for aortic disease severity in patients with MFS. Even without knowing the function of a particular DMP, using the level of hyper- or hypomethylation showed predictive value for occurrence of clinical events. Interestingly, DNA methylation biomarkers have become a major area of research as potential alternative diagnostic method for various forms of cancer [15–17]. For example, in lung cancer it detects the early stage of disease [76]. Another study conducted in cancer patients described that DNA methylation data could improve early detection beyond known risk factors [77]. Identified DNA methylation markers may not only constitute a precision medicine tool, but may also help elucidate novel mechanisms of treatment. Both, to detect early onset of aortic disease and to unravel novel treatment mechanisms, DNA methylation may provide insight in MFS.

While we did not observe significant DMPs related to other MFS characteristics besides aortic characteristics, among the genes behind the DMPs that were significantly associated with aortic diameters, some of these genes have known functions representing other MFS characteristics. According to The Human Gene Database 'GeneCards<sup>®</sup>', seven genes were identified (SAM4A, EHP1, IGF2BP3, PTPRN2, PIP4K2A, SLC2A11, and BMP15) that are involved in glucose transport/insulin signaling, which regulates tissue growth and cellular survival. Moreover, indicated in the same database, of these seven genes, variants in four of them (SAM4A, IGF2BP3, PIP4K2A, and BMP15) and additionally HDAC4 have been associated with abnormal body height as is often observed in patients with FBN1 mutations (tall MFS patients or short stature acromelic dysplasia patients [78, 79]). Disturbed insulin/Akt signaling may thus be a determinant for the excessive growth in MFS patients, which deserves further investigation. Interestingly, also SEMA3A mutations may cause short stature, as can be observed in FBN1 mutation patients with acromelic dysplasias [58]. Moreover, the two genes FAM50B and NAGPA are associated with adolescent idiopathic scoliosis (GeneCards<sup>®</sup>), which is a common feature in MFS patients [78, 80].

In conclusion, our EWAS study in MFS patients provides novel leads that are worth looking into in future

MFS research. Furthermore, it would be interesting to follow-up on the use of methylation status as biomarker assay for aorta disease severity or genes and pathways involved in the pathological processes in MFS.

### Limitations

A potential limitation is the use of whole-blood samples. As DNA methylation is tissue specific, we ideally would have analyzed connective tissue, such as aortic or skin tissue. However, sampling of aortic tissue in epidemiological studies is not realistic, while the use of DNA methylation from skin tissue would be of interest for comparison with our blood-derived results. Nevertheless, peripheral blood is easy to access and thought to represent a signature that is concordant with other tissue types [81]. Although research on the extrapolation of peripheral blood to cardiac tissue DNA methylation patterns is scarce, good results between cardiovascular biopsies and peripheral blood samples on DNA methylation were published previously in heart failure patients [82]. Nevertheless, it would still be necessary to investigate the reproducibility between aortic tissue and peripheral blood DNA methylation before any translational outlook could be accomplished. Moreover, epigenetic biomarkers derived from routine blood samples are more convenient for clinical practice. Another limitation is that we only have blood samples taken at baseline. Longitudinal studies assessing repeated measurement of DNA methylation would be needed to assess whether the epigenetic changes identify severity of aortic pathology.

### Conclusion

In summary, this first methylation study in MFS patients has identified a small number of differentially methylated loci in the DNA of whole-blood samples that are significantly associated with aortic diameters, aortic diameter *change* and aortic *events*. Of the underlying genes, 35% of these genes are associated with cardiovascular disease, and are thus of interest to evaluate further. Investigating methylation regions, revealed an interesting gene cluster of protocadherins on chromosome 5, which could be functionally involved in MFS by altered cell adhesion.

Further studies are needed to confirm and extend these findings, including evaluation of the functional relevance of the loci and replication in other MFS populations. Our findings add to the slowly growing literature on the epigenetic architecture of MFS patients.

### Abbreviations

DMP: Differentially methylated positions; DMR: Differentially methylated regions; FBN1: Fibrillin-1; MFS: Marfan syndrome.

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13148-021-01204-4>.

**Additional file 1.** Supplemental material.

### Acknowledgements

Not applicable.

### Authors' contributions

AHZ, BJMM and MG proposed and initiated the COMPARE trial. AHZ and VW defined the research strategy of the methylation study. AHZ provided statistical expertise. AJAHS, MPB, and JT are our collaborators. AHZ, VW and MMA drafted the manuscript. BJMM and MG revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

### Funding

This work was supported by private funding via the AMC Foundation.

### Availability of data and materials

The datasets analyzed during the current study will become available from the corresponding author on reasonable non-commercial request.

### Declarations

#### Ethics approval and consent to participate

The COMPARE trial was conducted with approval of the Medical Ethical Committee of the Amsterdam UMC—location AMC. Written informed consent was obtained from all participants.

#### Consent for publication

Not applicable.

#### Competing interests

V. de Waard obtained grants from the AMC Foundation, supporting M.M. van Andel during the conduct of the study. The other authors have nothing to disclose. A.H. Zwinderman and B.J.M. Mulder obtained grants from BBMRI\_NL supporting measurements of methylation levels.

#### Author details

<sup>1</sup>Department of Cardiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. <sup>2</sup>Department of Radiology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>3</sup>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. <sup>4</sup>Department of Cardiology, Radboud University Hospital, Nijmegen, The Netherlands. <sup>5</sup>Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. <sup>6</sup>Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, Amsterdam, The Netherlands. <sup>7</sup>Department of Medical Biochemistry, Amsterdam UMC, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.

Received: 17 September 2021 Accepted: 27 November 2021

Published online: 11 December 2021

### References

- Collod-Beroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. *Hum Mutat.* 2003;22(3):199–208.
- Franken R, Groenink M, de Waard V, Feenstra HM, Scholte AJ, van den Berg MP, et al. Genotype impacts survival in Marfan syndrome. *Eur Heart J.* 2016;37(43):3285–90.
- Franken R, Teixeira-Tura G, Brion M, Forteza A, Rodriguez-Palmares J, Gutierrez L, et al. Relationship between fibrillin-1 genotype and severity of cardiovascular involvement in Marfan syndrome. *Heart (Br Cardiac Soc).* 2017;103(22):1795–9.

4. Franken R, Heesterbeek TJ, de Waard V, Zwiderman AH, Pals G, Mulder BJM, et al. Diagnosis and genetics of Marfan syndrome. *Expert Opin Orphan Drugs*. 2014;2(10):1049–62.
5. Franken R, den Hartog AW, Radonic T, Micha D, Maugeri A, van Dijk FS, et al. Beneficial outcome of losartan therapy depends on Type of FBN1 mutation in Marfan syndrome. *Circ Cardiovasc Genet*. 2015;8(2):383–8.
6. Arnaud P, Milleron O, Hanna N, Ropers J, Ould Ouali N, Affoune A, et al. Clinical relevance of genotype-phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants. *Genet Med Off J Am College Med Genet*. 2021.
7. Benarroch L, Aubart M, Gross MS, Arnaud P, Hanna N, Jondeau G, et al. Reference expression profile of three FBN1 transcript isoforms and their association with clinical variability in Marfan syndrome. *Genes (Basel)*. 2019;10(2):128.
8. Aubart M, Gross MS, Hanna N, Zabot MT, Sznajder M, Detaint D, et al. The clinical presentation of Marfan syndrome is modulated by expression of wild-type FBN1 allele. *Hum Mol Genet*. 2015;24(10):2764–70.
9. Aubart M, Gazal S, Arnaud P, Benarroch L, Gross MS, Buratti J, et al. Association of modifiers and other genetic factors explain Marfan syndrome clinical variability. *Eur J Hum Genet EJHG*. 2018;26(12):1759–72.
10. Mordi IR, Forsythe RO, Gellatly C, Iskandar Z, McBride OM, Saratzis A, et al. Plasma desmosine and abdominal aortic aneurysm disease. *J Am Heart Assoc*. 2019;8(20):e013743.
11. Franken R, den Hartog AW, de Waard V, Engele L, Radonic T, Lutter R, et al. Circulating transforming growth factor-beta as a prognostic biomarker in Marfan syndrome. *Int J Cardiol*. 2013;168(3):2441–6.
12. Yin X, Wang S, Fellows AL, Barallobre-Barreiro J, Lu R, Davaapil H, et al. Glycoproteomic analysis of the aortic extracellular matrix in Marfan patients. *Arterioscler Thromb Vasc Biol*. 2019;39(9):1859–73.
13. Benke K, Ágg B, Mátyás G, Szokolai V, Harsányi G, Szilveszter B, et al. Gene polymorphisms as risk factors for predicting the cardiovascular manifestations in Marfan syndrome. Role of folic acid metabolism enzyme gene polymorphisms in Marfan syndrome. *Thromb Haemost*. 2015;114(4):748–56.
14. Arai Y, Umeyama K, Takeuchi K, Okazaki N, Hichiwa N, Yashima S, et al. Establishment of DNA methylation patterns of the Fibrillin1 (FBN1) gene in porcine embryos and tissues. *J Reprod Dev*. 2017;63(2):157–65.
15. Koroknai V, Szász I, Hernandez-Vargas H, Fernandez-Jimenez N, Cuenin C, Hecceg Z, et al. DNA hypermethylation is associated with invasive phenotype of malignant melanoma. *Exp Dermatol*. 2020;29(1):39–50.
16. Sharma P, Bhunia S, Poojary SS, Tekcham DS, Barbhuiya MA, Gupta S, et al. Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease. *Tumour Biol*. 2016;37(11):14687–99.
17. Li WH, Zhang H, Guo Q, Wu XD, Xu ZS, Dang CX, et al. Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer. *Dis Markers*. 2015;2015:657570.
18. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. *Eur Heart J*. 2013;34(45):3491–500.
19. Radonic T, de Witte P, Baars MJ, Zwiderman AH, Mulder BJ, Groenink M. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. *Trials*. 2010;11:3.
20. Loeyes BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. The revised Ghent nosology for the Marfan syndrome. *J Med Genet*. 2010;47(7):476–85.
21. van Andel MM, Indrakusuma R, Jalalzadeh H, Balm R, Timmermans J, Scholte AJ, et al. Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicenter randomized controlled COMPARE trial. *Eur Heart J*. 2020;41(43):4181–7.
22. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinform*. 2012;13:86.
23. Echarri A, Pavón DM, Sánchez S, García-García M, Calvo E, Huerta-López C, et al. An Abl-FBP17 mechanosensing system couples local plasma membrane curvature and stress fiber remodeling during mechanoadaptation. *Nat Commun*. 2019;10(1):5828.
24. Rai A, Bleimling N, Vetter IR, Goody RS. The mechanism of activation of the actin binding protein EHBP1 by Rab8 family members. *Nat Commun*. 2020;11(1):4187.
25. Kaufman L, Potla U, Coleman S, Dikay S, Hata Y, Kurihara H, et al. Up-regulation of the homophilic adhesion molecule sidekick-1 in podocytes contributes to glomerulosclerosis. *J Biol Chem*. 2010;285(33):25677–85.
26. Wang Z, Peng T, Wu H, He J, Li H. HAP1 helps to regulate actin-based transport of insulin-containing granules in pancreatic  $\beta$  cells. *Histochem Cell Biol*. 2015;144(1):39–48.
27. Crosas-Molist E, Meirelles T, Lopez-Luque J, Serra-Peinado C, Selva J, Caja L, et al. Vascular smooth muscle cell phenotypic changes in patients with Marfan syndrome. *Arterioscler Thromb Vasc Biol*. 2015;35(4):960–72.
28. Humphrey JD, Schwartz MA, Tellides G, Milewicz DM. Role of mechanotransduction in vascular biology: focus on thoracic aortic aneurysms and dissections. *Circ Res*. 2015;116(8):1448–61.
29. Hohl M, Wagner M, Reil JC, Müller SA, Tauchnitz M, Zimmer AM, et al. HDAC4 controls histone methylation in response to elevated cardiac load. *J Clin Investig*. 2013;123(3):1359–70.
30. Mathias RA, Guise AJ, Cristea IM. Post-translational modifications regulate class IIa histone deacetylase (HDAC) function in health and disease. *Mol Cell Proteomics*. 2015;14(3):456–70.
31. Nagarajan N, Oka S, Sadoshima J. Modulation of signaling mechanisms in the heart by thioredoxin 1. *Free Radical Biol Med*. 2017;109:125–31.
32. Wang Y, Hu G, Liu F, Wang X, Wu M, Schwarz JJ, et al. Deletion of yes-associated protein (YAP) specifically in cardiac and vascular smooth muscle cells reveals a crucial role for YAP in mouse cardiovascular development. *Circ Res*. 2014;114(6):957–65.
33. Usui T, Morita T, Okada M, Yamawaki H. Histone deacetylase 4 controls neointimal hyperplasia via stimulating proliferation and migration of vascular smooth muscle cells. *Hypertension*. 2014;63(2):397–403.
34. Zhang B, Dong Y, Liu M, Yang L, Zhao Z. miR-149-5p inhibits vascular smooth muscle cells proliferation, invasion, and migration by targeting histone deacetylase 4 (HDAC4). *Med Sci Monit*. 2019;25:7581–90.
35. Li Y, Li L, Qian Z, Lin B, Chen J, Luo Y, et al. Phosphatidylinositol 3-kinase-DNA methyltransferase 1-miR-1281-Histone Deacetylase 4 regulatory axis mediates platelet-derived growth factor-induced proliferation and migration of pulmonary artery smooth muscle cells. *J Am Heart Assoc*. 2018;7(6):e007572.
36. Abend A, Shkedi O, Fertouk M, Caspi LH, Kehat I. Salt-inducible kinase induces cytoplasmic histone deacetylase 4 to promote vascular calcification. *EMBO Rep*. 2017;18(7):1166–85.
37. Kim GR, Cho SN, Kim HS, Yu SY, Choi SY, Ryu Y, et al. Histone deacetylase and GATA-binding factor 6 regulate arterial remodeling in angiotensin II-induced hypertension. *J Hypertens*. 2016;34(11):2206–19.
38. Pedroza AJ, Tashima Y, Shad R, Cheng P, Wirka R, Churovich S, et al. Single-cell transcriptomic profiling of vascular smooth muscle cell phenotype modulation in Marfan syndrome aortic aneurysm. *Arterioscler Thromb Vasc Biol*. 2020;40:2195–211.
39. Li Y, Ren P, Dawson A, Vasquez HG, Ageedi W, Zhang C, et al. Single-cell transcriptome analysis reveals dynamic cell populations and differential gene expression patterns in control and aneurysmal human aortic tissue. *Circulation*. 2020;142(14):1374–88.
40. Wang Z, Cui M, Shah AM, Ye W, Tan W, Min YL, et al. Mechanistic basis of neonatal heart regeneration revealed by transcriptome and histone modification profiling. *Proc Natl Acad Sci USA*. 2019;116(37):18455–65.
41. Akerberg AA, Burns CE, Burns CG. Exploring the activities of RBPMS proteins in myocardial biology. *Pediatr Cardiol*. 2019;40(7):1410–8.
42. Huang RT, Xue S, Wang J, Gu JY, Xu JH, Li YJ, et al. CASZ1 loss-of-function mutation associated with congenital heart disease. *Gene*. 2016;595(1):62–8.
43. Su W, Wang RC, Lohano MK, Wang L, Zhu P, Luo Y, et al. Identification of two mutations in PCDHGA4 and SLFN14 genes in an atrial septal defect family. *Curr Med Sci*. 2018;38(6):989–96.
44. Oguri M, Kato K, Yokoi K, Yoshida T, Watanabe S, Metoki N, et al. Assessment of a polymorphism of SDK1 with hypertension in Japanese Individuals. *Am J Hypertens*. 2010;23(1):70–7.
45. Takeuchi F, Isono M, Katsuya T, Yamamoto K, Yokota M, Sugiyama T, et al. Blood pressure and hypertension are associated with 7 loci in the Japanese population. *Circulation*. 2010;121(21):2302–9.
46. Xie G, Myint PK, Voora D, Laskowitz DT, Shi P, Ren F, et al. Genome-wide association study on progression of carotid artery intima media thickness over 10 years in a Chinese cohort. *Atherosclerosis*. 2015;243(1):30–7.
47. Neves JS, Vale C, von Hafe M, Borges-Canha M, Leite AR, Almeida-Coelho J, et al. Thyroid hormones and modulation of diastolic function: a

- promising target for heart failure with preserved ejection fraction. *Ther Adv Endocrinol Metab.* 2020;11:2042018820958331.
48. Pol CJ, Muller A, Simonides WS. Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: an adaptative response or part of the problem? *Heart Fail Rev.* 2010;15(2):133–42.
  49. Ali MM, Naquiallah D, Qureshi M, Mirza MI, Hassan C, Masrur M, et al. DNA methylation profile of genes involved in inflammation and autoimmunity correlates with vascular function in morbidly obese adults. *Epigenetics.* 2021:1–17.
  50. Takata M, Amiya E, Watanabe M, Omori K, Imai Y, Fujita D, et al. Impairment of flow-mediated dilation correlates with aortic dilation in patients with Marfan syndrome. *Heart Vessels.* 2014;29(4):478–85.
  51. Lomeli O, Perez-Torres I, Marquez R, Criales S, Mejia AM, Chiney C, et al. The evaluation of flow-mediated vasodilation in the brachial artery correlates with endothelial dysfunction evaluated by nitric oxide synthase metabolites in Marfan syndrome patients. *Front Physiol.* 2018;9:965.
  52. Chen PY, Chu A, Liao WW, Rubbi L, Janzen C, Hsu FM, et al. Prenatal growth patterns and birthweight are associated with differential DNA methylation and gene expression of cardiometabolic risk genes in human placentas: a discovery-based approach. *Reprod Sci.* 2018;25(4):523–39.
  53. Agha G, Mendelson MM, Ward-Caviness CK, Joehanes R, Huan T, Gondalia R, et al. Blood leukocyte DNA methylation predicts risk of future myocardial infarction and coronary heart disease. *Circulation.* 2019;140(8):645–57.
  54. Wang L, Hauser ER, Shah SH, Seo D, Sivashanmugam P, Exum ST, et al. Polymorphisms of the tumor suppressor gene *LSAMP* are associated with left main coronary artery disease. *Ann Hum Genet.* 2008;72(Pt 4):443–53.
  55. Dungan JR, Qin X, Horne BD, Carlquist JF, Singh A, Hurdle M, et al. Case-only survival analysis reveals unique effects of genotype, sex, and coronary disease severity on survivorship. *PLoS ONE.* 2016;11(5):e0154856.
  56. Grossman TR, Gamliel A, Wessells RJ, Taghli-Lamalle O, Jepsen K, Ocorr K, et al. Over-expression of *DSCAM* and *COL6A2* cooperatively generates congenital heart defects. *PLoS Genet.* 2011;7(11):e1002344.
  57. Pelleri MC, Gennari E, Locatelli C, Piovesan A, Caracausi M, Antonaros F, et al. Genotype-phenotype correlation for congenital heart disease in Down syndrome through analysis of partial trisomy 21 cases. *Genomics.* 2017;109(5–6):391–400.
  58. Gileta AF, Helgeson ML, Leonard JMM, Pyle LC, Subramanian HP, Arndt K, et al. Further delineation of a recognizable type of syndromic short stature caused by biallelic *SEMA3A* loss-of-function variants. *Am J Med Genet A.* 2021;185(3):889–93.
  59. Dimopoulos A, Sicko RJ, Kay DM, Rigler SL, Druschel CM, Caggana M, et al. Rare copy number variants in a population-based investigation of hypoplastic right heart syndrome. *Birth Defects Res.* 2017;109(1):8–15.
  60. Padgett RL, Mohite SS, Hoog TG, Justis BS, Green BE, Udan RS. Hemodynamic force is required for vascular smooth muscle cell recruitment to blood vessels during mouse embryonic development. *Mech Dev.* 2019;156:8–19.
  61. Bergwerff M, Gittenberger-de Groot AC, Wisse LJ, DeRuiter MC, Wessels A, Martin JF, et al. Loss of function of the *Prx1* and *Prx2* homeobox genes alters architecture of the great elastic arteries and ductus arteriosus. *Virchows Arch.* 2000;436(1):12–9.
  62. Chen X, Gao B, Ponnusamy M, Lin Z, Liu J. *MEF2* signaling and human diseases. *Oncotarget.* 2017;8(67):112152–65.
  63. Liao YC, Lo SH. Tensins—emerging insights into their domain functions, biological roles and disease relevance. *J Cell Sci.* 2021;134(4):jcs254029.
  64. Dina C, Bouatia-Naji N, Tucker N, Delling FN, Toomer K, Durst R, et al. Genetic association analyses highlight biological pathways underlying mitral valve prolapse. *Nat Genet.* 2015;47(10):1206–11.
  65. Kyryachenko S, Georges A, Yu M, Berrandou T, Guo L, Bruneval P, et al. Chromatin accessibility of human mitral valves and functional assessment of MVP risk loci. *Circ Res.* 2021;128(5):e84–101.
  66. Rybczynski M, Mir TS, Sheikhzadeh S, Bernhardt AM, Schach C, Treede H, et al. Frequency and age-related course of mitral valve dysfunction in the Marfan syndrome. *Am J Cardiol.* 2010;106(7):1048–53.
  67. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet.* 2011;43(4):333–8.
  68. Aravani D, Morris GE, Jones PD, Tattersall HK, Karamanavi E, Kaiser MA, et al. *HHIPL1*, a gene at the 14q32 coronary artery disease locus, positively regulates hedgehog signaling and promotes atherosclerosis. *Circulation.* 2019;140(6):500–13.
  69. Meester JAN, Verstraeten A, Alaerts M, Schepers D, Van Laer L, Loeys BL. Overlapping but distinct roles for NOTCH receptors in human cardiovascular disease. *Clin Genet.* 2019;95(1):85–94.
  70. Baldini A, Fulcoli FG, Illingworth E. *Tbx1*: transcriptional and developmental functions. *Curr Top Dev Biol.* 2017;122:223–43.
  71. Pancho A, Aerts T, Mitsogiannis MD, Seuntjens E. Protocadherins at the crossroad of signaling pathways. *Front Mol Neurosci.* 2020;13:117.
  72. Tsai TY, Sikora M, Xia P, Colak-Champollion T, Knaut H, Heisenberg CP, et al. An adhesion code ensures robust pattern formation during tissue morphogenesis. *Science (New York, NY).* 2020;370(6512):113–6.
  73. Yagi H, Liu X, Gabriel GC, Wu Y, Peterson K, Murray SA, et al. The genetic landscape of hypoplastic left heart syndrome. *Pediatr Cardiol.* 2018;39(6):1069–81.
  74. Ortega A, Gil-Cayuela C, Tarazón E, García-Manzanares M, Montero JA, Cinca J, et al. New cell adhesion molecules in human ischemic cardiomyopathy. *PCDHGA3* implications in decreased stroke volume and ventricular dysfunction. *PLoS ONE.* 2016;11(7):e0160168.
  75. Quijada P, Trembley MA, Small EM. The role of the epicardium during heart development and repair. *Circ Res.* 2020;126(3):377–94.
  76. Hong Y, Kim WJ. DNA methylation markers in lung cancer. *Curr Genom.* 2021;22(2):79–87.
  77. Domingo-Relloso A, Huan T, Haack K, Riffo-Campos AL, Levy D, Fallin MD, et al. DNA methylation and cancer incidence: lymphatic-hematopoietic versus solid cancers in the Strong Heart Study. *Clin Epigenet.* 2021;13(1):43.
  78. Bitterman AD, Sponseller PD. Marfan syndrome: a clinical update. *J Am Acad Orthop Surg.* 2017;25(9):603–9.
  79. Stanley S, Balic Z, Hubmacher D. Acromelic dysplasias: how rare musculoskeletal disorders reveal biological functions of extracellular matrix proteins. *Ann N Y Acad Sci.* 2021;1490(1):57–76.
  80. Sponseller PD, Hobbs W, Riley LH 3rd, Peyerit RE. The thoracolumbar spine in Marfan syndrome. *J Bone Joint Surg Am.* 1995;77(6):867–76.
  81. Kato N, Loh M, Takeuchi F, Verweij N, Wang X, Zhang W, et al. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. *Nat Genet.* 2015;47(11):1282–93.
  82. Meder B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Frese K, Lai A, et al. Epigenome-wide association study identifies cardiac gene patterning and a novel class of biomarkers for heart failure. *Circulation.* 2017;136(16):1528–44.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

